全文获取类型
收费全文 | 153339篇 |
免费 | 12152篇 |
国内免费 | 3998篇 |
专业分类
耳鼻咽喉 | 1052篇 |
儿科学 | 2856篇 |
妇产科学 | 1974篇 |
基础医学 | 8283篇 |
口腔科学 | 3035篇 |
临床医学 | 21826篇 |
内科学 | 25092篇 |
皮肤病学 | 2412篇 |
神经病学 | 7890篇 |
特种医学 | 4582篇 |
外国民族医学 | 42篇 |
外科学 | 13222篇 |
综合类 | 23048篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 9279篇 |
眼科学 | 2080篇 |
药学 | 12960篇 |
179篇 | |
中国医学 | 11863篇 |
肿瘤学 | 17789篇 |
出版年
2024年 | 237篇 |
2023年 | 2792篇 |
2022年 | 4023篇 |
2021年 | 7087篇 |
2020年 | 6703篇 |
2019年 | 5807篇 |
2018年 | 5526篇 |
2017年 | 6085篇 |
2016年 | 6539篇 |
2015年 | 6400篇 |
2014年 | 12029篇 |
2013年 | 14470篇 |
2012年 | 9957篇 |
2011年 | 10324篇 |
2010年 | 8249篇 |
2009年 | 7434篇 |
2008年 | 7143篇 |
2007年 | 7542篇 |
2006年 | 6537篇 |
2005年 | 5689篇 |
2004年 | 4553篇 |
2003年 | 3994篇 |
2002年 | 3252篇 |
2001年 | 2851篇 |
2000年 | 2324篇 |
1999年 | 1834篇 |
1998年 | 1499篇 |
1997年 | 1267篇 |
1996年 | 1069篇 |
1995年 | 941篇 |
1994年 | 744篇 |
1993年 | 566篇 |
1992年 | 509篇 |
1991年 | 465篇 |
1990年 | 392篇 |
1989年 | 337篇 |
1988年 | 336篇 |
1987年 | 281篇 |
1986年 | 221篇 |
1985年 | 258篇 |
1984年 | 226篇 |
1983年 | 168篇 |
1982年 | 166篇 |
1981年 | 163篇 |
1980年 | 130篇 |
1979年 | 123篇 |
1978年 | 65篇 |
1977年 | 42篇 |
1976年 | 49篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
31.
32.
目的探讨品管圈在植入式静脉输液港(IVAP)患者护理中的应用。方法选取本院2018年10月-2018年12月IVAP患者30例作为对照组,2019年1月-2019年3月品管圈活动干预后IVAP患者30例作为观察组。对照组采用常规护理措施,观察组采用品管圈活动干预后的护理措施。比较两组IVAP患者并发症的发生率和对护理工作的满意度。结果观察组导管堵塞1例;并发症发生率为3.33%(1/30)。对照组感染4例,血栓2例,导管堵塞4例;并发症发生率为33.33%(10/30)。观察组并发症发生率低于对照组(P <0.05)。观察组对优质服务、技术水平、关怀、出院指导、护理总满意度评分分别为(42.39±5.27)分、(31.49±4.32)分、(22.25±4.69)分、(20.26±4.91)分、(112.24±10.38)分;对照组分别为(38.65±4.91)分、(28.68±4.26)分、(19.96±4.30)分、(19.94±4.63)分、(103.37±10.12)分;观察组对优质服务、技术水平、关怀、出院指导、护理总满意度评分均高于对照组(P <0.05)。结论通过品管圈活动干预后的护理措施明显降低IVAP患者并发症的发生率,提高患者对护理工作的满意度。 相似文献
33.
34.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
35.
36.
37.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。 相似文献
38.
Alexandra B. Morshed Rachel G. Tabak Cynthia D. Schwarz Debra Haire-Joshu 《Journal of nutrition education and behavior》2019,51(2):237-244
Objective
To examine whether a healthy weight intervention embedded in the Parents as Teachers (PAT) home visiting program, which was previously found to improve mothers’ body mass index (BMI) and obesity-related behaviors, changed the BMI of preschool children or maternal feeding practices.Methods
This stratified randomized trial included preschool-aged children at risk for overweight whose mothers were overweight or had obesity (n?=?179). The Healthy Eating and Active Living Taught at Home (HEALTH) intervention was based on the Diabetes Prevention Program. Differences were examined using repeated-measures mixed-ANOVA models.Results
Compared with PAT usual care, the HEALTH intervention had no effect on children's BMI or maternal feeding practices. However, combined analyses showed that children's BMI percentile decreased (P??=?.007), BMI z-scores were maintained (P??=?.19), and 3 of 8 feeding practices improved over time (P < .05).Conclusions and Implications
Additional research is needed to assess the effectiveness of PAT to prevent preschool-age obesity using rigorous designs (eg, group-randomized trials) and to identify its active components. HEALTH is ready to be scaled up to prevent maternal weight gain through embedding within the national PAT program. 相似文献39.
40.